2
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
59
Carcinoma, Hepatocellular
46
Colorectal Neoplasms
33
Stomach Neoplasms
31
Esophageal Squamous Cell Carcinoma
27
Squamous Cell Carcinoma of Head and Neck
20
Esophageal Neoplasms
14
Small Cell Lung Carcinoma
13
Neoplasm Metastasis
13
Lung Neoplasms
13
Rectal Neoplasms
12
Head and Neck Neoplasms
12
Advanced Solid Tumor
12
Triple Negative Breast Neoplasms
11
Cholangiocarcinoma
11
Nasopharyngeal Carcinoma
10
Melanoma
10
Uterine Cervical Neoplasms
9
Recurrence
9
Neoplasms
9
Colonic Neoplasms
9
Pancreatic Neoplasms
7
Urinary Bladder Neoplasms
6
Solid Tumor
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Sarcoma
5
Lymphoma, Extranodal NK-T-Cell
5
Lymphoma
5
Hodgkin Disease
5
Interventions
Mitomycin
3
Hyperthermic Intraperitoneal Chemotherapy
3
Surveys and Questionnaires
2
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
Capecitabine
2
Bromelains
2
Acetylcysteine
2
tislelizumab
1
molgramostim
1
irinotecan sucrosofate
1
cryoprecipitate coagulum
1
Tacrolimus
1
Standard of Care
1
Specimen Handling
1
Sirolimus
1
Referral and Consultation
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Pharmacogenomic Testing
1
Observation
1
Nivolumab
1
Methods
1
Magnetic Resonance Spectroscopy
1
Lansoprazole
1
Ipilimumab
1
Ifosfamide
1
Gemcitabine
1
Floxuridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pseudomyxoma Peritonei
×
tislelizumab
×
Clear all
NCT07341360
2026-01-14
Pseudovax
Oslo University Hospital
Phase EARLY_PHASE1
Recruiting
10 enrolled